BioPharmSignal logoBioPharmSignal

Biotech News

aTyr Pharma to Participate in Upcoming Investor Conferences

aTyr Pharma (ATYR)aTyr PharmaCompany update

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming

Open original release

Related news

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-05-11 20:01 EST

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

NRIXNurix Therapeutics2026-05-13 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conferences

KYMRKymera2026-05-06 11:00 EST

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

ARGXArgenx2026-05-27 05:00 EST

argenx to Present at Upcoming Investor Conferences

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

NRIXNurix Therapeutics2026-04-07 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conference

CLDXCelldex Therapeutics2026-04-13 20:01 EST

Celldex to Present at Upcoming Investor Conference

AVTXAvalo Therapeutics2026-07-22 11:00 EST

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

View all latest news

aTyr Pharma

aTyr Pharma is a biotechnology company focused on extracellular biology and inflammatory disease. Its story is centered on using novel biology to address serious immune-mediated conditions.

Recent company news

ATYRaTyr Pharma2026-05-15 12:00 EST

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

ATYRaTyr Pharma2026-05-13 20:01 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

ATYRaTyr Pharma2026-05-11 20:01 EST

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

ATYRaTyr Pharma2026-03-05 21:01 EST

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

ATYRaTyr Pharma2026-02-20 21:01 EST

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.49 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States